Ignite Creation Date:
2024-05-05 @ 6:46 PM
Last Modification Date:
2024-10-26 @ 9:37 AM
Study NCT ID:
NCT00546520
Status:
COMPLETED
Last Update Posted:
2016-12-07
First Post:
2007-10-18
Brief Title:
Effect of Inhaled Ciclesonide in Adult Patients With Asthma BY9010M1-125
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A 3-period Double-blind Cross-over Study on the Onset of Action of Inhaled Ciclesonide 7 Days of 400 mcg Sid Versus 800 mcg Bid Versus Placebo on Airway Responsiveness to Adenosine Monophosphate AMP Sputum Eosinophiles and Exhaled Breath Nitric Oxide NO in Patients With Asthma
Status:
COMPLETED
Status Verified Date:
2016-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Ciclesonide is a novel inhaled corticosteroid for the treatment of asthma In this study the effect of ciclesonide on airway hyperresponsiveness AHR exhaled nitric oxide NO and induced sputum inflammatory biomarkers will be evaluated
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None